A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)

This prospective study aimed to develop reproducible diagnostic criteria for sporadic Burkitt lymphoma (BL), applicable to routine practice, and to evaluate the efficacy of dose-modified (dm) CODOX-M/IVAC in patients diagnosed using these criteria. The study was open to patients with an aggressive B...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Mead, Graham M., Barrans, Sharon L., Qian, Wendi, Walewski, Jan, Radford, John A., Wolf, Max, Clawson, Simon M., Stenning, Sally P., Yule, Claire L., Jack, Andrew S.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2008
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2532802/
https://ncbi.nlm.nih.gov/pubmed/18612102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-03-145128
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items